TEFA Family Prevention: Glutenfree Diet to Preserve Beta-cell Function

Type 1 Diabetes Clinical Trial

— TEFA  

Official title:

TEFA TEDDY Family Prevention - Gluten Free Diet to Preserve Beta-cell Function in Subjects With Islet Autoimmunity.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02605148
• Other study ID #: TEFA/2015
• Status: Active, not recruiting
• Phase: N/A
• Start date: December 2015
• Est. completion date: December 2022

Study information

• Verified date: October 2021
• Source: Lund University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the effect of Gluten Free Diet (GFD) on beta-cell function and glucose metabolism in subjects with one or several islet autoantibodies without and with dysglycemia at baseline. Additionally, all subjects will be given treatment with Vitamin D, omega fatty acids and probiotics.

Subjects will be randomized to GFD or normal diet during 18 months. Beta cell function will be evaluated at baseline, and during follow-up by glucose tolerance tests.

Description:

The design is a randomized controlled study to determine the safety and the effect of gluten free diet during 18 months on beta-cell function and glucose metabolism. Lead-in and nonstop supplement cocktail including vitamin D, omega fatty acids and probiotics will be used to equalize differences to reduce known confounders. All study subjects will meet with a dietician to obtain a 3-day diet record and to receive instructions on a healthy normal diet or GFD.

Subjects (n=60) at 2-49.99 years of age positive for one or several islet autoantibodies will be recruited. Subjects with one islet autoantibody have done one or several oral glucose tolerance test (OGTT) prior to the baseline visit. One islet autoantibody positive subjects are only eligible if they have dysglycemia. All subjects will be randomized based on baseline intravenous glucose tolerance test (IvGTT) and OGTT into subjects without and with dysglycemia at baseline.

Beta-cell function and glucose metabolism (alternating IvGTT and OGTT) will be assessed at baseline and after 6, 12, 18 months of treatment and after 6 months of wash out on a normal healthy diet.

Adverse events and safety Adverse event will be obtained at visits and during the study, which will be monitored.

It is expected that subjects with one or several islet autoantibodies will show a loss compared to baseline of beta-cell function and glucose control. GFD is expected to reduce the loss in subjects on a healthy diet.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: December 2022
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 49 Years

Eligibility

Inclusion Criteria:

1. Subjects from two (2) to 49,99 years of age.

2. At least one type 1 diabetes-associated autoantibody (to glutamic acid (GADA), insulin (IAA), insulinoma-associated protein 2 (IA-2A) or zinktransporter 8 (ZnT8R/W/QA) in subjects with impaired glucose metabolism OR at least two type 1 diabetes-associated autoantibodies, regardless of normal or impaired glucose metabolism.

3. Written informed consent from research subject. If a child, also from the child's parents or legal acceptable representative(s) according to local regulations.

Exclusion Criteria:

1. Ongoing treatment with immunosuppressant therapy (topical or inhaled steroids are accepted).

2. Diabetes.

3. Treatment with any oral or injected anti-diabetic medications.

4. Significantly abnormal hematology results at screening.

5. Participation in other clinical trials with a new chemical entity within the previous 3 months.

6. History of hypercalcemia.

7. Presence of associated serious disease or condition.

8. Diabetes-protective HLA-DQ6-allele.

-

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Glucose Intolerance
• Prediabetes
• Prediabetic State
• Type 1 Diabetes

Intervention

Dietary Supplement:
• Gluten free diet
Gluten free diet during 18 months.
• Omega 3 fatty acid
Omega 3 fatty acid
• Vitamin D
Vitamin D 800 U/day
• Probiotics
Probiotics

Locations

Country	Name	City	State
Sweden	Lund University, Department of Clinical Sciences Malmö	Malmö

Sponsors (2)

Lead Sponsor	Collaborator
Lund University	Juvenile Diabetes Research Foundation

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in first phase insulin response (FPIR) from IvGTT	Change in First phase insulin response from IvGTT during follow-up	24 months
Primary	Change in area under the curve (AUC) C-peptide	Change in AUC C-peptide from OGTT during follow-up	24 months
Primary	Change in glucose metabolism	Change from normal to impaired glucose metabolism during follow-up	24 months
Secondary	Incidence of Treatment-Emergent Adverse Events	To evaluate safety of GFD compared to recommended normal diet in the placebo group in subjects supplemented with lead in and nonstop treatment with a cocktail including vitamin D, omega fatty acids and probiotics.	24 months